Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-26T14:26:41.813Z Has data issue: false hasContentIssue false
  • English
  • Français

The course of behavioral problems in elderly nursing home patients with dementia when treated with antipsychotics

Published online by Cambridge University Press:  22 June 2009

B. C. Kleijer ,
R. J. van Marum ,
A. C. G. Egberts ,
P. A. F. Jansen ,
D. Frijters ,
E. R. Heerdink  and
M. Ribbe
B. C. Kleijer
Affiliation:
Department of Geriatrics, University Medical Center Utrecht, The Netherlands
R. J. van Marum*
Affiliation:
Department of Geriatrics, University Medical Center Utrecht, The Netherlands
A. C. G. Egberts
Affiliation:
Department of Clinical Pharmacy, University Medical Center Utrecht, The Netherlands Department of Pharmaceutical Sciences, University of Utrecht, The Netherlands
P. A. F. Jansen
Affiliation:
Department of Geriatrics, University Medical Center Utrecht, The Netherlands
D. Frijters
Affiliation:
Department of Nursing Home Medicine, VU Medical Center and EMGO-Institute, Amsterdam, The Netherlands
E. R. Heerdink
Affiliation:
Department of Pharmaceutical Sciences, University of Utrecht, The Netherlands
M. Ribbe
Affiliation:
Department of Nursing Home Medicine, VU Medical Center and EMGO-Institute, Amsterdam, The Netherlands
*
Correspondence should be addressed to: Dr. R. J. van Marum, Department of Geriatrics, University Medical Center Utrecht, The Netherlands, PO Box 85500, 3508 GA Utrecht, The Netherlands. Phone: +31 887558280; Fax: +31 302544397. Email: [email protected].
Get access

Abstract

Background: Although antipsychotic treatment of behavioral problems in dementia is common, studies investigating the course of these symptoms in nursing homes are scarce. Our primary objective is therefore to describe the course of behavioral problems during antipsychotic treatment in a large sample of elderly nursing home patients with dementia.

Methods: The course of behavioral problems during antipsychotic treatment was studied by comparing the characteristics of patients before, during and after antipsychotic treatment. The study was conducted using the VURAIDB, a database with over 40,000 assessments of over 10,000 nursing home residents in the Netherlands. We used the Challenging Behavior Profile (CBP) to measure an overall behavior score.

Results: In total, 556 patients starting with antipsychotics were studied. Of these, 101 (18.2%) improved and 260 (46.8%) deteriorated at three months on the behavior score, compared with their scores before therapy (z = −7.955; P<0.0001). Patients with severe challenging behavior showed improvement more often than patients with mild disturbances. The course of behavioral symptoms after withdrawal was evaluated in 520 patients. Of these patients, 352 (68%) remained stable or improved at 3 months compared with their scores before withdrawal (z = −0.697; p = 0.486), this figure was 58% at 6 months after withdrawal (z = −2.77; p = 0.006).

Conclusions: During treatment of nursing home residents with dementia with antipsychotics the severity of most behavioral problems continues to increase in most patients, with only one out of six patients showing improvement. After withdrawal of antipsychotics, behavioral problems remained stable or improved in 58% of patients.

Keywords

antipsychoticselderlybehaviordementia
Type
Research Article
Information
International Psychogeriatrics , Volume 21 , Issue 5 , October 2009 , pp. 931 - 940
Copyright
Copyright © International Psychogeriatric Association 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aalten, P., de Vugt, M. E., Jaspers, N., Jolles, J. and Verhey, F. R. (2005). The course of neuropsychiatric symptoms in dementia. Part II: relationships among behavioural sub-syndromes and the influence of clinical variables. International Journal of Geriatric Psychiatry, 20, 531–536.CrossRefGoogle ScholarPubMed
Alanen, H. M., Finne-Soveri, H., Noro, A. and Leinonen, E. (2006). Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. International Journal of Geriatric Psychiatry, 21, 288–295.CrossRefGoogle Scholar
Ballard, C. G. et al. (2001). A 1-year follow-up study of behavioral and psychological symptoms in dementia among people in care environments. Journal of Clinical Psychiatry, 62, 631–636.CrossRefGoogle ScholarPubMed
Ballard, C. G. et al. (2004). A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. Journal of Clinical Psychiatry, 65, 114–119.CrossRefGoogle ScholarPubMed
Ballard, C. G. et al. (2008). A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine, 5, e76.CrossRefGoogle ScholarPubMed
Ballard, C. G. et al. (2009). The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurology, 8, 151–157.CrossRefGoogle ScholarPubMed
Bergh, S. and Engedal, K. (2008). The withdrawal of antipsychotics and antidepressants from patients with dementia and BPSD living in nursing homes – an open pilot study. International Journal of Geriatric Psychiatry, 23, 877–879.CrossRefGoogle ScholarPubMed
Bharucha, A. J. et al. (2008). Prevalence of behavioral symptoms: comparison of the minimum data set assessments with research instruments. Journal of the American Medical Directors Association, 9, 244–250.CrossRefGoogle ScholarPubMed
Bridges-Parlet, S., Knopman, D. and Steffes, S. (1997). Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. Journal of Geriatric Psychiatry and Neurology, 10, 119–126.CrossRefGoogle ScholarPubMed
Briesacher, B. A. et al. (2005). The quality of antipsychotic drug prescribing in nursing homes. Archives of Internal Medicine, 165, 1280–1285.CrossRefGoogle ScholarPubMed
Bronskill, S. E. et al. (2004). Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. Journal of the American Geriatrics Society, 52, 749–755.CrossRefGoogle ScholarPubMed
Carson, S., McDonagh, M. S. and Peterson, K. (2006). A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia. Journal of the American Geriatrics Society, 54, 354–361.CrossRefGoogle ScholarPubMed
Cohen-Mansfield, J., Lipson, S., Werner, P., Billig, N., Taylor, L. and Woosley, R. (1999). Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Archives of Internal Medicine, 159, 1733–1740.CrossRefGoogle ScholarPubMed
de Deyn, P. P. et al. (1999). A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology, 53, 946–955.CrossRefGoogle ScholarPubMed
Frederiksen, K., Tariot, P. and De, J. E. (1996). Minimum Data Set Plus (MDS+) scores compared with scores from five rating scales. Journal of the American Geriatrics Society, 44, 305–309.CrossRefGoogle ScholarPubMed
Gerritsen, D. L., Achterberg, W. P., Steverink, N., Pot, A. M., Frijters, D. H. and Ribbe, M. W. (2008). The MDS Challenging Behavior Profile for long-term care. Aging and Mental Health, 12, 116–123.CrossRefGoogle ScholarPubMed
Gill, S. S. et al. (2005). Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ, 330, 445–451.CrossRefGoogle ScholarPubMed
Gobert, M. and D'hoore, W. (2005). Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. International Journal of Geriatric Psychiatry, 20, 712–721.CrossRefGoogle ScholarPubMed
Hartmaier, S. L., Sloane, P. D., Guess, H. A. and Koch, G. G. (1994). The MDS Cognition Scale: a valid instrument for identifying and staging nursing home residents with dementia using the minimum data set. Journal of the American Geriatrics Society, 42, 1173–1179.CrossRefGoogle Scholar
Hawes, C., Morris, J. N., Phillips, C. D., Mor, V., Fries, B. E. and Nonemaker, S. (1995). Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS). Gerontologist, 35, 172–178.CrossRefGoogle ScholarPubMed
Hawes, C., Morris, J. N., Phillips, C. D., Fries, B. E., Murphy, K. and Mor, V. (1997). Development of the nursing home Resident Assessment Instrument in the USA. Age and Ageing, 26 (Suppl. 2), 19–25.CrossRefGoogle ScholarPubMed
Hien, L. T. T. et al. (2005). Atypical antipsychotic medications and risk of falls in residents of aged care facilities. Journal of the American Geriatrics Society, 53, 1290–1295.CrossRefGoogle ScholarPubMed
Katz, I. R., Jeste, D. V., Mintzer, J. E., Clyde, C., Napolitano, J. and Brecher, M. (1999). Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. Journal of Clinical Psychiatry, 60, 107–115.CrossRefGoogle ScholarPubMed
Kleijer, B. C., van Marum, R. J., Egberts, A. C., Jansen, P. A., Knol, W. and Heerdink, E. R. (2008). Risk of cerebrovascular events in elderly users of antipsychotics. Journal of Psychopharmacology. E-publication ahead of print, 17 July, doi: 10.1177/0269881108093583.CrossRefGoogle Scholar
Knol, W., van Marum, R. J., Jansen, P. A., Souverein, P. C., Schobben, A. F. and Egberts, A. C. (2008). Antipsychotic drug use and risk of pneumonia in elderly people. Journal of the American Geriatrics Society, 56, 661–666.CrossRefGoogle ScholarPubMed
Kuehn, B. M. (2005). FDA warns antipsychotic drugs may be risky for elderly. JAMA, 293, 2462.Google ScholarPubMed
Kuehn, B. M. (2008). FDA: antipsychotics risky for elderly. JAMA, 300, 379–380.Google ScholarPubMed
Lee, P. E. et al. (2005). Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. Journal of the American Geriatrics Society, 53, 1374–1379.CrossRefGoogle ScholarPubMed
Liperoti, R. et al. (2007). Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. Journal of Clinical Psychiatry, 68, 929–934.CrossRefGoogle ScholarPubMed
Morris, J., Fries, B. E., Morris, S. A. (1999). Scaling ADLs within the MDS. Journal of Gerontology: Medical Sciences, 54A, 11, M546–M553.Google Scholar
Ruths, S., Straand, J., Nygaard, H. A., and Aarsland, D. (2008). Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study – the Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 23, 889–895.CrossRefGoogle Scholar
Schneider, L. S., Pollock, V. E. and Lyness, S. A. (1990). A meta-analysis of controlled trials of neuroleptic treatment in dementia. Journal of the American Geriatrics Society, 38, 553–563.CrossRefGoogle ScholarPubMed
Schneider, L. S., Dagerman, K. S. and Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934–1943.CrossRefGoogle ScholarPubMed
Schneider, L. S., Dagerman, K. and Insel, P. S. (2006a). Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. American Journal of Geriatric Psychiatry, 14, 191–210.CrossRefGoogle ScholarPubMed
Schneider, L. S. et al. (2006b). Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New England Journal of Medicine, 355, 1525–1538.CrossRefGoogle ScholarPubMed
Selbaek, G., Kirkevold, O. and Engedal, K. (2008). The course of psychiatric and behavioral symptoms and the use of psychotropic medication in patients with dementia in Norwegian nursing homes–a 12-month follow-up study. American Journal of Geriatric Psychiatry, 16, 528–536.CrossRefGoogle ScholarPubMed
Setoguchi, S., Wang, P. S., Alan, B. M., Canning, C. F., Kaci, L. and Schneeweiss, S. (2008). Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. Journal of the American Geriatrics Society, 56, 1644–1650.CrossRefGoogle ScholarPubMed
Shorr, R. I., Fought, R. L. and Ray, W. A. (1994). Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA, 271, 358–362.CrossRefGoogle ScholarPubMed
Snowden, M. et al. (1999). Validity and responsiveness of the Minimum Data Set. Journal of the American Geriatrics Society, 47, 1000–1004.CrossRefGoogle ScholarPubMed
Snowden, M., Sato, K. and Roy-Byrne, P. (2003). Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature. Journal of the American Geriatrics Society, 51, 1305–1317.CrossRefGoogle ScholarPubMed
Sultzer, D. L. et al. (2008). Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. American Journal of Psychiatry, 165, 844–854.CrossRefGoogle ScholarPubMed
Thapa, P. B., Meador, K. G., Gideon, P., Fought, R. L. and Ray, W. A. (1994). Effects of antipsychotic withdrawal in elderly nursing home residents. Journal of the American Geriatrics Society, 42, 280–286.CrossRefGoogle ScholarPubMed
Valiyeva, E., Herrmann, N., Rochon, P. A., Gill, S. S. and Anderson, G. M. (2008). Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. Canadian Medical Association Journal, 179, 438–446.CrossRefGoogle ScholarPubMed
van Dijk, K. N., de Vries, C. S., van den Berg, P. B., Brouwers, J. R. and de Jong-van den Berg, LT (2000). Drug utilisation in Dutch nursing homes. European Journal of Clinical Pharmacology, 55, 765–771.CrossRefGoogle ScholarPubMed
van Reekum, R. et al. (2002). A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. International Psychogeriatrics, 14, 197–210.CrossRefGoogle ScholarPubMed
Wang, P. S. et al. (2005). Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine, 353, 2335–2341.CrossRefGoogle ScholarPubMed
Zornberg, G. L. and Jick, H. (2000). Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. The Lancet, 356, 1219–1223.CrossRefGoogle ScholarPubMed
Zuidema, S. U., Derksen, E., Verhey, F. R. and Koopmans, R. T. (2007). Prevalence of neuropsychiatric symptoms in a large sample of Dutch nursing home patients with dementia. International Journal of Geriatric Psychiatry, 22, 632–638.CrossRefGoogle Scholar